Hemostasis imbalance in experimental hypertension

Molecular Medicine

Volumn 8, Issue 4, 2002, Pages 169-178

  Corseaux, Delphine ^a   Ollivier, Véronique ^a   Fontaine, Vincent ^a   Huisse, Marie Geneviève ^a   Philippe, Monique ^a   Louedec, Liliane ^a   Vranckx, Roger ^a   Ravanat, Catherine ^a   Lanza, François ^a   Angles Cano, Edouardo ^a   Guillin, Marie Claude ^a   Michel, Jean Baptiste ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; ZOFENOPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY WALL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GLOMERULUS; HEMOSTASIS; HYPERTENSION; KIDNEY BLOOD VESSEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; THROMBOSIS; ZYMOGRAPHY;

EID: 0036050907     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402009     Document Type: Article

References (43)

1. Elevated systolic blood pressure as a cardiovascular risk factor
2. The pathogenesis of coronary artery disease and the acute coronary syndromes
3. Hypertension, coronary artery and cerebrovascular diseases in the population. Has epidemiology changed in the last decades?
4. Common carotid artery intima-media thickness and brain infarction: The Etude du Profil Genetique de l'infarctus Cerebral (GENIC) case-control study
5. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase
6. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage
7. Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats
8. In vitro alteration of aortic vascular reactivity in chronic L-NAME induced hypertension
9. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: Modulation of proinflammatory signals
10. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis
11. Chronic blockade of nitric oxide synthase activity induces pro-inflammatory phenotype in the arterial wall. Prevention by angiotensin II antagonism
12. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats
13. Improved survival in rats administered NG-nitro L-arginine methyl ester due to converting enzyme inhibition
14. Relationship between endothelial function and fibrinolysis in early hypertension
15. Structural biology of tissue factor, the initiator of thrombogenesis in vivo
16. Regulation of the tissue factor gene
17. GPV is a marker of in vivo platelet activation - Study in a rat thrombosis model
18. Quantitative assessment of procoagulant activity in isolated rat glomeruli
19. Regulation of renin release is impaired after nitric oxide inhibition
20. Selective isolation of rat aortic wall layers and their cell types in culture - Application to converting enzyme activity measurement
21. L'expansion Scientifique Française
22. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor
23. Failure of L-nitroarginine to inhibit the activity of aortic inducible nitric oxide synthase
24. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition
25. Nitric oxide released from activated platelets inhibits platelet recruitment
26. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature
27. Hypertension-induced end-organ damage: A new transgenic approach to an old problem
28. 2+ mobilization and protein kinase C activation
29. 1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy
30. Increased activity of nuclear factor-kappa participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats
31. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide
32. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: Inhibition with dietary L-arginine
33. Tissue factor pathway inhibitor
34. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiological role for EPI as a natural anticoagulant
35. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells
36. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
37. Relative lipophilicities and structural-pharmacological considerations of various ACE inhibitors
38. Losartan inhibits thromboxane A-2-induced platelet aggregation vascular constriction in spontaneously hypertensive rats
39. Inhibition of platelet aggregability by losartan in essential hypertension
40. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation
41. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
42. Association of blood pressure with fibrinolytic potential in the Framingham offspring population
43. Antihypertensive drug treatment and fibrinolytic function